ASH 2018: Professor Peter Hillmen on the Combination of Ibrutinib and Obinutuzumab in CLL: Timing Matters
Day 1 at ASH (American Society of Hematology) Annual Meeting 2018 in San Diego, the world’s largest hematology meeting, is ending for us around 11 PM.
Scientific presentations don’t start until tomorrow, but we have already been busy. And there is a huge buzz about what’s happening in CLL.
Tomorrow we are on the go from 7:30 AM to 11 PM with hardly a break, so I am not sure I will be up for an update, but today is in the bag.
It’s already been an amazing meeting and the best is yet to come. The treatment of CLL is fundamentally changing for the better! I will leave the references and links to later posts, but this is my chance to quickly share the breaking news at the end of long day.
Stay strong. We are all in this together.
Brian Koffman
Related posts
